『Today in ENT Allergy: AAOA's Podcast』のカバーアート

Today in ENT Allergy: AAOA's Podcast

Today in ENT Allergy: AAOA's Podcast

著者： Today in ENT Allergy: AAOA's Podcast
無料で聴く

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
The Resource for ENT Allergists© 2020 American Academy of Otolaryngic Allergy
エピソード
  • Classifying Chronic Rhinosinusitis What EPOS 2020 Changes

    Classifying Chronic Rhinosinusitis What EPOS 2020 Changes
    2026/08/25
    Podcast Host: Scott Fortune, MD, FAAOA Podcast Guests: Meha Fox, MD, FAAOA; Peter Filip, MD, FAAOA If you’ve trained in the last decade, you probably learned to classify chronic rhinosinusitis as one of two things: CRS with nasal polyps or CRS without nasal polyps. That’s CRSwNP and CRSsNP. Simple. Clean. Easy to document. But here’s the problem — that binary has been quietly failing us for years. It doesn’t tell us why a patient has polyps. It doesn’t predict who will respond to biologics. And it doesn’t explain why two patients with identical CT scans can have completely different disease trajectories. EPOS 2020 — the European Position Paper on Rhinosinusitis and Nasal Polyps — rewired how we should think about this disease. Today we’re going to walk through their classification framework, explain the biological logic behind it, and talk about what this means for how you actually manage patients in your clinic. Listen to this podcast to learn more. Key References: Fokkens WJ, et al. EPOS 2020: European Position Paper on Rhinosinusitis and NasalPolyps 2020. Rhinology. 2020;58(Suppl S29):1-464. Additional Suggested Reading: Laidlaw TM, Mullol J, et al. Biologics for CRSwNP and AERD. J Allergy Clin Immunol Pract. 2021.Soler ZM, et al. Eosinophilic CRS across the United States. Am J Rhinol Allergy. 2022.Stevens WW, et al. Central Compartment Atopic Disease. Am J Rhinol Allergy. 2015.Mullol J, Han JK, Laidlaw TM, Hopkins C, Peters AT, Pfaar O, Desrosiers M, Lee SE, Lane AP, Chen C, Chon Y, Ponnarambil SS, Foster A, Lindsley AW, Ambrose CS. Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT). Int Forum Allergy Rhinol. 2026 May;16(5):484-494. doi: 10.1002/alr.70090. Epub 2026 Jan 6. PMID: 41493192; PMCID: PMC13147228. Key Terms Defined in Episode: CRS — Chronic RhinosinusitisCRSwNP—Chronic Rhinosinusitis with Nasal PolypsCRSsNP—Chronic Rhinosinusitis without Nasal PolypsEPOS — European Position Paper on Rhinosinusitis and Nasal PolypsAFRS — Allergic Fungal RhinosinusitisCCAD — Central Compartment Atopic DiseaseeCRS — Eosinophilic CRSType 2 inflammation — Th2/ILC2-mediated, IL-4/IL-5/IL-13 cytokine signature, eosinophil-dominantNon-eCRS — Non-eosinophilic CRS, includes neutrophilic and other endotypesDupilumab — IL-4Rα antagonist (Dupixent); FDA approved for CRSwNPMepolizumab / Benralizumab — Anti-IL-5 biologics For more: www.AAOAllergy.org Watch the YouTube version of the podcast here.
    続きを読む 一部表示
    18 分
  • Rare Eosinophilic Disease Part 2 – Diagnostic Challenges & the Role of the ENT

    Rare Eosinophilic Disease Part 2 – Diagnostic Challenges & the Role of the ENT
    2024/04/23
    Are you missing rare eosinophilic disease diagnoses? Join an expert multidisciplinary panel for a podcast series highlighting the diagnostic challenges of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss) and what the otolaryngologist needs to know. Moderated by Dr. Jennifer Villwock. Rare Eosinophilic Disease Part 2 – Diagnostic Challenges & the Role of the ENT Listen to 2 expert otolaryngologists, Drs. Michael Platt and Ashoke Khanwalkar, in conjunction with their pulmonologist (Dr. Praveen Akuthota) and rheumatologist (Dr. Anisha Dua) colleagues, review the nuances of the ENT presentation in patients with EGPA including diagnostic tests, the role of biopsy and tips around referrals. Listen to Part 1 This is a non-CME disease state educational podcast series brought to you by the AAOA and sponsored by GSK. The information presented is scientific and non-promotional in nature. The panelists are practicing physicians paid by GSK to share their knowledge and expertise. Trademarks are owned by or licensed to the GSK group of companies.©2024 GSK group of companies or its licensor.
    続きを読む 一部表示
    21 分
  • Rare Eosinophilic Disease Part 1– A Multidisciplinary Approach

    Rare Eosinophilic Disease Part 1– A Multidisciplinary Approach
    2024/04/23
    Listen to Drs. Praveen Akuthota (pulmonologist), Anisha Dua (rheumatologist), and Michael Platt (otolaryngologist) provide an overview of EGPA and highlight what findings might increase the level of suspicion for rare disease.
    続きを読む 一部表示
    22 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません